2023 World Conference on Lung Cancer (Posters)-P2.29. Harnessing Artificial Intelligence to Expand Lung Cancer Clinical Trial Opportunities in Spain

Pdf Summary

A presentation titled "Harnessing Artificial Intelligence to Expand Lung Cancer Clinical Trial Opportunities in Spain" will be given at the WCLC 2023 conference. The presentation will focus on a novel app and web-based platform called Trialing, which was developed to provide up-to-date information on clinical trials and allow for direct patient referrals.<br /><br />The Trialing platform is designed for healthcare professionals and features a clinical trial search engine powered by artificial intelligence. By selecting specific features of a patient's disease, healthcare professionals are presented with a list of trials that match the patient's criteria. The platform is continually updated with clinical trials open for recruitment throughout Spain. Healthcare professionals can also refer anonymized patients directly through the platform.<br /><br />In 2022, 1047 oncologists registered on the Trialing platform, with 52% selecting lung cancer as their area of interest. A total of 681 patient referrals to clinical trials were made through the platform, with 21% of these referrals being for lung cancer patients. Most of the referred patients had metastatic disease, and a significant number of referrals were for phase 1 clinical trials.<br /><br />Among the lung cancer referrals, 50% were for clinical trials that included at least one biomarker as an inclusion criterion. The Trialing platform was found to be efficient, with users taking an average of only 60 seconds to find a clinical trial. The receiving centers also responded promptly to referral requests, with a confirmation of receipt time of less than 20 hours.<br /><br />Overall, the Trialing platform provides a useful tool for oncologists in Spain, as demonstrated by its uptake among healthcare professionals and the referrals made through the platform. The platform has a particular focus on metastatic non-small cell lung cancer, with a significant number of referrals targeting molecularly driven lung cancer. Additionally, patients with small cell lung cancer are often referred to early-phase trials.

Asset Subtitle

Edurne Arriola Aperribay

Meta Tag

Speaker Edurne Arriola Aperribay

Topic Global Health, Health Services & Health Economics: Digital Solutions

Keywords

Artificial Intelligence

Lung Cancer

Clinical Trial Opportunities

Spain

Trialing

App

Web-based Platform

Healthcare Professionals

Clinical Trial Search Engine

Patient Referrals